Sommer J, Borgmann SO, Gontscharuk V, Zaharia OP, Maalmi H, Herder C, Wagner R, Strassburger K, Schön M, Burkart V, Szendroedi J, Pfeiffer AFH, Bornstein S, Blüher M, Seissler J, Birkenfeld AL, Meyhöfer S, Roden M, and Icks A
Background: The subjective experiences of individuals living with diabetes is commonly assessed with patient-reported outcomes (PROs; eg, depression symptoms, wellbeing, health-related quality of life [HRQOL], and diabetes-related distress). Cluster analyses have identified novel diabetes subtypes differing in phenotypic and metabolic characteristics. We aimed to investigate associations between these subtypes and PROs and whether subtype predicted PROs 5 years later., Methods: Baseline (<12 months after a diabetes diagnosis) and 5-year follow-up data were collected from German Diabetes Study (GDS) participants. Multiple regressions were applied to analyse associations between diabetes subtypes and depression symptoms (Center for Epidemiologic Studies Depression Scale), wellbeing (WHO-5), HRQOL (SF-36), and diabetes-related distress (Problem Areas in Diabetes Scale)., Findings: Cluster analyses at baseline (n=1391) identified participants with severe autoimmune diabetes (SAID, 417 [30%]), severe insulin-deficient diabetes (SIDD, 33 [2%]), severe insulin-resistant diabetes (SIRD, 150 [11%]), mild obesity-related diabetes (MOD, 354 [25%]), and mild age-related diabetes (MARD, 437 [31%]). At baseline, multiple regression analyses showed that participants with SIRD had higher depression symptoms than participants with MARD and lower physical HRQOL than all other subtypes. Participants with SAID reported higher depression symptoms and lower mental HRQOL than participants with MARD, higher physical HRQOL than participants with MARD and MOD, and higher diabetes-related distress than most other subtypes. At the 5-year follow-up, clustering predicted no statistically significant changes in PROs after adjustment for multiple testing, whereas descriptive analyses demonstrated that individuals with SIRD were more likely to experience clinically relevant depression symptoms (16% vs 6%) and low wellbeing (31% vs 14%), respectively, than individuals with MARD., Interpretation: Diabetes subtypes already differ in PROs at diabetes diagnosis. Our analyses had limited predictive power during follow-up. However, our findings suggest that clustering could predict future changes in depression symptoms., Funding: The GDS was initiated and financed by the German Diabetes Center, which is funded by the German Federal Ministry of Health, the Ministry of Culture and Science of the state of North Rhine-Westphalia, and by the German Federal Ministry of Education and Research to the German Center for Diabetes Research., Translation: For the German translation of the abstract see Supplementary Materials section., Competing Interests: Declaration of interests The research of MR and CH is also supported by grants from the European Community (HORIZON-HLTH-2022-STAYHLTH-02–01: Panel A) to the INTERCEPT-T2D consortium. The research of MR is further supported by the German Science Foundation (DFG; CRC/SFB 1116/2 B12; RTG/GRK 2576 vivid, Project 3 and 493659010 Future4CSPMM), the Schmutzler Stiftung and the programme “Profilbildung 2020”, an initiative of the Ministry of Culture and Science of the State of Northrhine Westphalia, Boehringer Ingelheim, and Novo Nordisk. MR also reports honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Kenes Group, Madrigal, and MSD, consulting fees for Echosens, Novo Nordisk, and Target RWE, and participation for advisory boards from Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. The research of CH is also supported by the DFG. RW reports honoraria for lectures, presentations, or speaker's bureaus from Eli Lilly, Boehringer Ingelheim, Novo Nordisk, and Sanofi Aventis; travel support from NovoNordisk; and honoraria for advisory boards from Eli Lilly and Akcea Therapeutics. The research of AFHP is supported by the following grants: EU AI-DAPT (No. 101135826); EFSD/Boehringer Ingelheim European Research Programme (No. 98103); BMFW-Forschungskreis der Ernährungsindustrie (No. 21701). He also reports honoraria from Novo Nordisk, Berlin-Chemie, Sanofi, SCIARC, Berufsverband Deutscher Internistinnen und Internisten Wiesbaden, Lilly, AstraZeneca, Abbott, Nestlé, and FOMF. MB declares receiving honoraria for lectures or as a consultant from the following companies: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk, Novartis, and Sanofi. The research of HM is supported by a grant from EFSD/Novo Nordisk Foundation (grant number NNF22SA0079478) and the German Diabetes Association (DDG). SM has received travel expenses support and honoraria for speaking and consulting activities from Biomarin, Lilly Germany, Novo Nordisk, and Sanofi. She also states that her husband is an employee at Novo Nordisk. All other authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)